Literature DB >> 12060770

Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype.

Niko Beerenwinkel1, Barbara Schmidt, Hauke Walter, Rolf Kaiser, Thomas Lengauer, Daniel Hoffmann, Klaus Korn, Joachim Selbig.   

Abstract

Drug resistance testing has been shown to be beneficial for clinical management of HIV type 1 infected patients. Whereas phenotypic assays directly measure drug resistance, the commonly used genotypic assays provide only indirect evidence of drug resistance, the major challenge being the interpretation of the sequence information. We analyzed the significance of sequence variations in the protease and reverse transcriptase genes for drug resistance and derived models that predict phenotypic resistance from genotypes. For 14 antiretroviral drugs, both genotypic and phenotypic resistance data from 471 clinical isolates were analyzed with a machine learning approach. Information profiles were obtained that quantify the statistical significance of each sequence position for drug resistance. For the different drugs, patterns of varying complexity were observed, including between one and nine sequence positions with substantial information content. Based on these information profiles, decision tree classifiers were generated to identify genotypic patterns characteristic of resistance or susceptibility to the different drugs. We obtained concise and easily interpretable models to predict drug resistance from sequence information. The prediction quality of the models was assessed in leave-one-out experiments in terms of the prediction error. We found prediction errors of 9.6-15.5% for all drugs except for zalcitabine, didanosine, and stavudine, with prediction errors between 25.4% and 32.0%. A prediction service is freely available at http://cartan.gmd.de/geno2pheno.html.

Entities:  

Mesh:

Year:  2002        PMID: 12060770      PMCID: PMC123057          DOI: 10.1073/pnas.112177799

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

Authors:  J Durant; P Clevenbergh; P Halfon; P Delgiudice; S Porsin; P Simonet; N Montagne; C A Boucher; J M Schapiro; P Dellamonica
Journal:  Lancet       Date:  1999-06-26       Impact factor: 79.321

2.  Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy.

Authors:  H Walter; B Schmidt; A Rascu; M Helm; B Moschik; C Paatz; M Kurowski; K Korn; K Uberla; T Harrer
Journal:  Antivir Ther       Date:  2000-12

3.  Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.

Authors:  S G Deeks; N S Hellmann; R M Grant; N T Parkin; C J Petropoulos; M Becker; W Symonds; M Chesney; P A Volberding
Journal:  J Infect Dis       Date:  1999-06       Impact factor: 5.226

4.  Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.

Authors:  R E Means; T Greenough; R C Desrosiers
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

5.  Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.

Authors:  L Hong; X C Zhang; J A Hartsuck; J Tang
Journal:  Protein Sci       Date:  2000-10       Impact factor: 6.725

6.  Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors.

Authors:  H Walter; B Schmidt; K Korn; A M Vandamme; T Harrer; K Uberla
Journal:  J Clin Virol       Date:  1999-06       Impact factor: 3.168

7.  A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.

Authors:  K Hertogs; M P de Béthune; V Miller; T Ivens; P Schel; A Van Cauwenberge; C Van Den Eynde; V Van Gerwen; H Azijn; M Van Houtte; F Peeters; S Staszewski; M Conant; S Bloor; S Kemp; B Larder; R Pauwels
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

8.  A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.

Authors:  B A Larder; S Bloor; S D Kemp; K Hertogs; R L Desmet; V Miller; M Sturmer; S Staszewski; J Ren; D K Stammers; D I Stuart; R Pauwels
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

9.  Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development.

Authors:  S Palmer; R W Shafer; T C Merigan
Journal:  AIDS       Date:  1999-04-16       Impact factor: 4.177

Review 10.  Managing resistance to anti-HIV drugs: an important consideration for effective disease management.

Authors:  A M Vandamme; K Van Laethem; E De Clercq
Journal:  Drugs       Date:  1999-03       Impact factor: 11.431

View more
  63 in total

1.  Evolution of document networks.

Authors:  Filippo Menczer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-27       Impact factor: 11.205

2.  A method for finding communities of related genes.

Authors:  Dennis M Wilkinson; Bernardo A Huberman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-02       Impact factor: 11.205

3.  Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes.

Authors:  Niko Beerenwinkel; Martin Däumer; Mark Oette; Klaus Korn; Daniel Hoffmann; Rolf Kaiser; Thomas Lengauer; Joachim Selbig; Hauke Walter
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

4.  Human immunodeficiency virus polymorphisms and zidovudine resistance.

Authors:  Emanuele Nicastri; Loredana Sarmati; Massimo Andreoni; Saverio G Parisi
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

5.  Predicting impaired glucose metabolism in women with polycystic ovary syndrome by decision tree modelling.

Authors:  M Möhlig; A Flöter; J Spranger; M O Weickert; T Schill; H W Schlösser; G Brabant; A F H Pfeiffer; J Selbig; C Schöfl
Journal:  Diabetologia       Date:  2006-09-14       Impact factor: 10.122

6.  Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance.

Authors:  Jing Zhang; Tingjun Hou; Wei Wang; Jun S Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-11       Impact factor: 11.205

7.  Use of sequence data generated in the Bayer Tru Gene genotyping assay to recognize and characterize non-subtype-b human immunodeficiency virus type 1 strains.

Authors:  Diane L Hirigoyen; Charles P Cartwright
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

8.  Recursive partitioning of resistant mutations for longitudinal markers based on a U-type score.

Authors:  Chengcheng Hu; Victor Degruttola
Journal:  Biostatistics       Date:  2011-05-19       Impact factor: 5.899

9.  Web resources for HIV type 1 genotypic-resistance test interpretation.

Authors:  Tommy F Liu; Robert W Shafer
Journal:  Clin Infect Dis       Date:  2006-04-28       Impact factor: 9.079

10.  minet: A R/Bioconductor package for inferring large transcriptional networks using mutual information.

Authors:  Patrick E Meyer; Frédéric Lafitte; Gianluca Bontempi
Journal:  BMC Bioinformatics       Date:  2008-10-29       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.